A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines
Completed · Phase 4 · NCT06218251
Conditions: Upper Facial Lines
At a glance
- Research payments reported, 2025
- $15,839
- U.S. investigators named
- 11
- Sites paid
- 9
- Planned or actual enrollment
- 100
About the trial
- Sponsor
- AbbVie
- Tested
- BOTOX (drug)
- Dates
- Started 2024-02-05; completion 2024-12-17
- Results posted
- Yes
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), lateral canthal lines (LCL), and forehead lines (FHL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. The purpose of this study is to evaluate participant satisfaction and natural outcomes following the administration of BOTOX Cosmetic in adult participants with upper facial lines (GL, LCL, and FHL). This is an open-label study in which all participants will receive active study treatment. Around 100 adult participants with an assessment of moderate to severe GL, LCL, and FHL, will be enrolled at approximately 10 sites in the United States and…
From ClinicalTrials.gov, last updated 2025-11-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $15,839 in research payments for this study in 2025 (12 payments).
Products named: Botox
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Amir Moradi, MD ENT (Otolaryngology) · Vista, CA
- Terrence C. Keaney, M.D Dermatology · Washington, DC
- Inti Fernandez, M.D General Practice · Miami, FL
- Carmen M. Kavali, MD Plastic Surgery · Atlanta, GA
- Martin P. Levinson, M.D. Pediatrics · Bingham Farms, MI
- Brad C. Klein, M.D. Neurology · Abington, PA
- Melissa P. Chiang, MD Dermatopathology · Spring, TX
- Peggy F. Linguist, M.D. Pediatrics · Waxahachie, TX
- Tolulope M. Olabintan, MD Family Medicine · Mansfield, TX
- Naila F. Siddiqi, MD Pediatrics · Houston, TX
- Patrick J. Hogan III, D.O. Neurology · Tacoma, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Pacific Clinical Innovations Inc $4,294
- Skin Dc PLLC $3,305
- Carmen Michelle Kavali MD PC $2,770
- Integrated Aesthetics $1,097
- The Maas Clinic $1,097
- Tennessee Clinical Research Center LLC $1,097
- Skin Wellness Dermatology $1,097
- Kavali Plastic Surgery and Skin Renewal Center $822
- Jeunesse Medispa PA $260
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.